The X-Grants Program is a Texas A&M initiative that brings together faculty and researchers in different fields. As part of the President’s Excellence Foundation, the Pancreatic Cancer Awareness Warrior Support Purple Ribbon hot Shirt aim is to showcase innovative ideas and research that tackle key problems in our modern world, from cancer therapy and treatment to agriculture. Commitment is $ 100 million over 10 years to fund faculty research.
Pancreatic Cancer Awareness Warrior Support Purple Ribbon hot Shirt, Hoodie, Long Sleeved, SweatShirt
Postmenopausal women with hormone receptors (HR) – positive, human epidermal growth factor receptor 2 (HER2) – negative breast cancer has spread to a limited number of lymph nodes and has a relatively low risk of recurrence, not receiving chemotherapy when added to hormone therapy, according to preliminary results from a clinical trial presented at the 2020 Breast Cancer Symposium in San Antonio.
This is the first evidence in a randomized phase III trial that postmenopausal women with HR-positive HER2 breast cancer and metastasis to one to three lymph nodes may abandon the Pancreatic Cancer Awareness Warrior Support Purple Ribbon hot Shirt chemotherapy. safely treat if their recurrence score in genetic tumor tissue test is 25 or less. The trial also demonstrated that, after an average of 5 years of follow-up, premenopausal women with similar disease characteristics benefited from chemotherapy.
The study, SWOG S1007, known as RxPONDER, was supported by the National Cancer Institute (NCI), part of the National Institutes of Health; Designed and led by Cancer Research Network SWOG (the link is external), and is conducted by the NCI National Network of Clinical Trials. the expander is an international effort, carried out at 632 locations in nine countries – United States, Canada, Mexico, Colombia, Ireland, France, Spain, South Korea, and Saudi Arabia.
Study lead author Kevin Kalinsky said: “Every day in clinics around the world, doctors grapple with the question of how to best treat women with the common form of breast cancer.”(link is external), MD, a SWOG investigator and Director of the Glenn Family Breast Center at the Winship Cancer Institute at Emory University, Atlanta. “These results are changing practice and demonstrating that postmenopausal women can be exempt from unnecessary chemotherapy and only receive hormone therapy. This will bring more clarity to the doctors and some relief for the patient. ”
TAILORx showed that postmenopausal women with lymphoma-negative breast cancer, HR-positive, HER2 negative, and recurrence scores of 25 or less in a genetic tumor tissue test found no benefit. from adding chemotherapy to hormone therapy versus hormone therapy alone. However, these results still leave the question of the Pancreatic Cancer Awareness Warrior Support Purple Ribbon hot Shirt most effective way to treat women diagnosed with advanced breast cancer that has spread to the lymph nodes.
Analysis of data from stored patient tumor samples in an earlier SWOG clinical trial, S8814, suggested that the recurrence score from lymph node-positive breast cancer patients was HR-positive. A negative HER2 and HER2 may predict chemotherapy benefits. The team began to find out if this was true, using a molecular test called the Oncotype DX Breast Recurrence Score.
The expander group screened 9,383 women with HR-positive, HER2-negative breast cancer, and one to three lymph nodes positive to identify those with recurrence scores of 25 or less. A total of 5,083 such patients were randomly assigned to receive either hormone alone or hormone therapy plus several months of intravenous chemotherapy with taxane and/or anthracyclines, chemotherapy drugs considered Standard treatment for this type of cancer.
All women were followed for an average of 5 years to evaluate the primary criterion of the trial, the ability to survive without an invasive disease, or IDFS, a measure of which patient developed lateral metastatic cancer. in addition to the breast, develops a new lump inside the breast, or dies of any cause. Survival is generally an extra endpoint.